Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: Optimization and in vivo appraisal

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3787-3802

  Elsheikh, Manal A ^a   Elnaggar, Yosra SR ^a   Gohar, Eman Y ^b   Abdallah, Ossama Y ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Biopharmaceutics Drug Disposition Classification System; Cremophor EL; endocrine organs; Selective estrogen receptor modulator; Self nanoemulsifying drug delivery system

Indexed keywords

CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; LABRASOL; NANOCARRIER; PLACEBO; POLYSORBATE 80; PROPANEDIOL DERIVATIVE; PROPYLENE GLYCOL MONOCAPRYLATE; RALOXIFENE; TRIETHANOLAMINE; UNCLASSIFIED DRUG;

ALKALINIZATION; ALKALINIZED SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL PARAMETERS; CLOUD POINT; CONTROLLED STUDY; DILUTION ROBUSTNESS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; EMULSIFICATION EFFICIENCY; FEMALE; FOOD; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; NANOEMULSION; NONALKALINIZED SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; NONHUMAN; PARTICLE SIZE; PHASE DIAGRAM; POLYDISPERSITY INDEX; PROCESS OPTIMIZATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; DRUG CARRIERS; DRUG STABILITY; EMULSIONS; EXCIPIENTS; FEMALE; GLYCEROL; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PHOTOMICROGRAPHY; RALOXIFENE; RATS; RATS, WISTAR; SOLUBILITY; VAGINAL SMEARS;

RATTUS NORVEGICUS;

EID: 84870315186     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33186     Document Type: Article

References (46)

1. Lee WL, Chao HT, Cheng MH, Wang PH. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas. 2008;60:92-107.
2. Lee WL, Chao HT, Cheng MH, Wang PH. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J Obstet Gynecol. 2008;47:24-31.
3. Williams-Brown MY, Salih SM, Xu X, etal. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 2011;126:78-86.
4. Cho CS, Shin TH, Lim JL, Moon KY, Kim DK, Choi YW. Stability-enhanced solid dispersion formulation of amorphous raloxifene hydrochloride. Korean J Chem Eng. 2010;27:1906-1909.
5. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717-733.
6. Jeong EJ, Lin H, Hu M. Disposition mechanisms of raloxifene in the human intestinal Caco-2model. J Pharmacol Exp Ther. 2004;310: 376-385.
7. Bayrak E, Lambrecht FY, Durkan K, Yilmaz O. In vitro evaluation, biodistribution in rats of radiolabeled raloxifene. Appl Radiat Isot. 2010;68:33-36.
8. Wempe MF, Wacher VJ, Ruble KM, etal. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. Int J Pharm. 2008;346:25-37.
9. Garg A, Singh S, Rao VU, Bindu K, Balasubramaniam J. Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. Drug Dev Ind Pharm. 2009;35:455-470.
10. Jagadish B, Yelchuri R, Bindu K, Tangi H, Maroju S, Rao VU. Enhanced dissolution and bioavailability of raloxifene hydrochloride by co-grinding with different superdisintegrants. Chem Pharm Bull. 2010;58:293-300.
11. Jha RK, Tiwari S, Mishra B. Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetic evaluation. AAPS Pharm Sci Tech. 2011;12:650-657.
12. Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci. 2011;3:442-448.
13. Chen Y, Jia X, Chen J, Wang J, Hu M. The pharmacokinetics of raloxifene and its interaction with apigenin in rat. Molecules. 2010;5: 8478-8487.
14. Kim AR, Lim SJ, Lee BJ. Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes. Int J Pharm. 2009;368:37-44.
15. Elnaggar YS, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm. 2009;380:133-141.
16. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine. 2010;5:1595-1616.
17. Nielsen FS, Petersen KB, Müllertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm. 2008;69:553-562.
18. Chen ML. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Deliv Rev. 2008;60: 768-777.
19. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673-691.
20. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci. 2008;35: 183-192.
21. Wang L, Dong J, Chen J, Eastoeb J, Li X. Design and optimization of a new self-nanoemulsifying drug delivery system. J Colloid Interface Sci. 2009;330:443-448.
22. Zhao Y, Wang C, Chow AHL, etal. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies. Int J Pharm. 2010;383: 170-177.
23. Nepal PR, Han HK, Choi HK. Preparation and in vitro-in vivo evaluation of Witepsol H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q10. Eur J Pharm Sci. 2010;39:224-232.
24. Ruan J, Liu J, Zhu D, etal. Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug-phospholipid complex technique. Int J Pharm. 2010;386:282-290.
25. Basalious EB, Shawky N, Badr-Eldin SM. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: Development and optimization. Int J Pharm. 2010;391:203-211.
26. Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. Colloids Surf B.2011;86:327-338.
27. Gupta S, Chavhan S, Sawant KK. Self-nanoemulsifying drug delivery system for adefovir dipivoxil: design, characterization, in vitro and ex vivo evaluation. Colloids Surf A. 2011;392:145-155.
28. Ghai D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker Talinolol. Nanomedicine. Epub September 14, 2011
29. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329:166-172.
30. Kadu PJ, Kushare SS, Thacker DD, Gattani SG. Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS). Pharm Dev Technol. 2011;16:65-74.
31. Kallakunta VR, Bandari S, Jukanti R, Veerareddy PR. Oral self emulsifying powder of lercanidipine hydrochloride: formulation and evaluation. Powder Technol. 2012;221:375-382.
32. US Pharmacopeial Convention. USP 34. Rockville: USP; 2011: 4113-4115.
33. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm. 2011;3:4-8.
34. Shanmugam S, Baskaran R, Balakrishnan P, Thapa P, Yong CS, Yoo BK. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) containing phosphatidylcholine for enhanced bioavailability of highly lipophilic bioactive carotenoid lutein. Eur J Pharm Biopharm. 2011;79: 250-257.
35. Yang Z, He X, Zhang Y. The determination of raloxifene in rat tissue using HPLC. Biomed Chromatogr. 2007;21:229-233.
36. Wempe MF, Wright C, Little JL, etal. Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS. Int J Pharm. 2009;370:93-102.
37. Patel J, Patel A, Raval M, Sheth N. Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res. 2011;2:9-16.
38. Kohli K, Chopra S, Phar D, Arora S, Khan R. Self-emulsifying drug delivery system: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15:958-965.
39. Row RC, Sheskey PJ, Weller PJ, editors. Handbook of Pharmaceutical Excipients. 4th ed. London: Pharmaceutical Press and American Pharmaceutical Association; 2003.
40. Tang SY, Manickam S, Wei TK, Nashiru B. Formulation development and optimization of a novel Cremophore EL-based nanoemulsion using ultrasound cavitation. Ultrason Sonochem. 2012;19:330-345.
41. Yang ZhY, Zhang ZF, He XB, Zhao GY, Zhang YQ. Validation of a novel HPLC method for the determination of raloxifene and its pharmacokinetics in rat plasma. Chromatographia. 2007;65: 197-201.
42. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos. 2002;30:694-700.
43. Marcondes FK, Bianchi FJ, Tanno AP. Determination of the estrus cycle phases of rats: helpful considerations. Braz J Biol. 2002;62: 609-614.
44. El-Mas MM, El-Gowilly SM, Gohar EY, Ghazal AR, Abdel-Rahman AA. Estrogen dependence of the renal vasodilatory effect of nicotine in rats: role of α7 nicotinic cholinergic receptor/eNOS signaling. Life Sci. 2011;88:187-193.
45. Fatouros DG, Karpf DM, Nielsen FS, Mullertz A. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag. 2007;3:591-604.
46. Celnikier DH. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol. 1999;85:23-29.